+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market by Product Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Ankylosing Spondylitis Market by Product Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Ankylosing Spondylitis Market by Product Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5292911
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ankylosing Spondylitis Market grew from USD 5.60 billion in 2024 to USD 6.09 billion in 2025. It is expected to continue growing at a CAGR of 8.35%, reaching USD 9.07 billion by 2030.

Unveiling the Current Challenges and Opportunities in Ankylosing Spondylitis Management

Ankylosing spondylitis poses unique challenges for patients, clinicians, and industry stakeholders due to its chronic, inflammatory nature and increasingly complex treatment milieu. This executive summary offers a distilled overview of the most pertinent developments, emerging therapies, policy shifts, and market dynamics shaping the future of ankylosing spondylitis management. It is designed to serve as a strategic compass for decision-makers seeking to navigate an environment marked by rapid innovation, evolving reimbursement landscapes, and varying regional adoption patterns.

Drawing on rigorous primary and secondary research, this report examines the current therapeutic armamentarium, including both biologic and small molecule interventions, and explores how emerging modalities such as JAK inhibitors and IL-17 antagonists are redefining treatment paradigms. Moreover, it contextualizes the influence of regulatory actions, supply chain considerations, and macroeconomic factors on pricing and access. By integrating quantitative intelligence with qualitative expert insights, this summary equips executive leadership with a holistic understanding of market opportunities, potential risks, and actionable pathways to achieve sustainable growth in an increasingly competitive arena.

Harnessing Breakthrough Developments Reshaping Ankylosing Spondylitis Care

The ankylosing spondylitis landscape is undergoing a profound transformation as groundbreaking therapeutic advances converge with digital innovation and new care delivery models. Biologics targeting tumor necrosis factor have long held a dominant position, yet second-generation molecules directed at IL-17 and IL-12/23 pathways are rapidly gaining traction, demonstrating enhanced efficacy and favorable safety profiles in clinical trials. Concurrently, the advent of highly selective JAK inhibitors marks a pivotal expansion in oral treatment options, addressing unmet patient needs for convenience and adherence.

Beyond pharmaceutical innovation, care delivery is reshaping through the adoption of telehealth platforms and home-based infusion services that enhance patient engagement and reduce the burden on hospital systems. Regulatory agencies are increasingly emphasizing real-world evidence to support label expansions, while payers are negotiating value-based contracts to contain costs and ensure optimal outcomes. As personalized medicine and biomarker-driven strategies emerge, diagnostics and digital monitoring tools will play an integral role in guiding treatment selection and disease management. These interlocking shifts herald a new era of patient-centric care and commercial opportunity.

Evaluating the Ripple Effects of 2025 US Tariffs on Treatment Accessibility

The introduction of enhanced tariffs by the United States government in 2025 has reverberated across the ankylosing spondylitis market, influencing drug pricing, supply chain resilience, and patient access. Increased duties on imported active pharmaceutical ingredients and finished biologics have exerted upward pressure on manufacturing expenditures, prompting manufacturers to reassess sourcing strategies and negotiate cost-sharing arrangements with contract development and manufacturing organizations. In response, several biopharma companies have accelerated plans for domestic API production to mitigate tariff exposure and fortify supply continuity.

Reimbursement dynamics have also been affected, as payers rebalance formulary tiers to absorb higher list prices while incentivizing biosimilar adoption for tumor necrosis factor inhibitors. Healthcare providers are navigating a tighter margin environment, which may influence prescribing patterns and limit the uptake of newer, higher-cost IL-17 antagonists or JAK inhibitors absent compelling real-world effectiveness data. Patient advocacy groups are engaging with policymakers to advocate for co-pay assistance programs and expanded insurance coverage to preserve affordable treatment pathways. Overall, the 2025 tariff adjustments underscore the need for agile commercial strategies and robust stakeholder collaboration to safeguard access and maintain growth trajectories.

Dissecting Market Dynamics Through Comprehensive Segmentation Analysis

A nuanced examination of product class segmentation reveals that biologics continue to command a leading share, propelled by longstanding tumor necrosis factor inhibitors and the surging interest in IL-17 and IL-12/23 inhibitors. Meanwhile, small molecule therapies, including conventional DMARDs and emerging JAK inhibitors, are carving out significant niches, particularly in patient segments seeking oral administration and more favorable safety profiles. Mechanism of action perspectives highlight the continued relevance of corticosteroids in acute flares, while novel pathways such as IL-17 blockade and selective JAK inhibition are garnering momentum as components of long-term disease management.

Route of administration insights demonstrate that injectable formulations, delivered via subcutaneous or intravenous infusion, remain prevalent for high-efficacy therapies, yet oral solutions and tablets are rapidly gaining favor due to convenience and adherence benefits. Topical creams and gels retain a smaller but stable market presence for symptomatic relief. Distribution channel analysis underscores the dominance of hospital and retail pharmacies for initial therapy provision, with specialty and online pharmacies growing in importance for chronic refill dynamics and patient support programs. End user trends reflect the primacy of hospitals and specialty clinics in diagnosis and treatment initiation, alongside rising utilization of homecare centers for ongoing infusions and patient education services.

Uncovering Regional Variations Influencing Market Trajectories

In the Americas, robust healthcare infrastructure, high per capita spending, and early adoption of innovative therapies have solidified the region’s leadership position. The United States remains the largest national market, driven by strong reimbursement frameworks and a mature biosimilars segment, while Canada’s public payer systems have facilitated broader access to novel agents under value-based agreements.

Europe, the Middle East, and Africa exhibit heterogeneous market behaviors, with Western Europe demonstrating rapid uptake of high-cost biologics and JAK inhibitors under centralized health technology assessments. In contrast, economies in the Middle East and Africa face challenges related to affordability and distribution infrastructure, leading to a preference for cost-effective small molecules and conventional DMARDs in many territories.

Asia-Pacific embodies dynamic growth potential, powered by expanding healthcare budgets, growing patient awareness, and localized manufacturing capabilities. Markets such as Japan and Australia are early investors in targeted therapies, whereas emerging economies in Southeast Asia and India are prioritizing generic small molecules and biosimilar entries to broaden patient access and contain spending.

Spotlighting Leading Innovators Driving Therapeutic Advances

Key industry leaders are distinguishing themselves through strategic investments in research collaborations, pipeline expansion, and manufacturing scale-up. Companies with established portfolios of tumor necrosis factor inhibitors are leveraging their extensive clinical and safety data to launch second-generation biologics targeting IL-17 and IL-12/23 pathways. At the same time, innovators focused on small molecules are advancing late-stage programs for JAK inhibitors, positioning these assets as potent oral alternatives with competitive differentiation in safety and dosing convenience.

Strategic partnerships between biopharma and contract manufacturing organizations are enhancing capacity to meet anticipated demand, particularly for subcutaneous injectable formats and complex monoclonal antibodies. In parallel, several firms are exploring digital therapeutics and patient support platforms to complement pharmacological regimens and drive improved adherence and outcomes. Mergers and acquisitions continue to reshape the competitive landscape, as larger players seek to diversify portfolios and secure early-stage assets with promising mechanisms of action. This dynamic environment underscores the importance of corporate agility and forward-looking R&D investments.

Strategic Roadmap for Industry Leaders to Navigate Emerging Trends

Industry leaders must adopt a multipronged strategy to thrive amid shifting market forces and stakeholder expectations. First, prioritizing investments in differentiated therapies, including next-generation biologics and selective small molecules, will be critical to maintaining competitive advantage and addressing unmet patient needs. Second, strengthening supply chain resilience through diversification of API sources and flexible manufacturing partnerships will mitigate risks associated with tariff impacts and global disruptions.

Third, proactive engagement with payers and policymakers to negotiate value-based contracts and patient assistance programs will help preserve access while aligning on outcomes. Fourth, integrating digital health solutions-from telemedicine platforms to remote monitoring devices-can enhance patient engagement, reduce administrative burdens, and generate real-world evidence to support label expansions. Finally, expanding geographic footprints in high-growth developing markets and tailoring market access strategies for affordability will unlock new revenue streams and foster sustainable growth in the ankylosing spondylitis arena.

Robust Methodological Framework Underpinning Our Insights

The insights presented in this executive summary derive from a robust methodological framework combining primary and secondary research. Primary research included in-depth interviews with key opinion leaders, payers, clinicians, and patient advocacy groups, enabling a granular understanding of therapeutic decision drivers and access barriers. Secondary research involved comprehensive analysis of scientific literature, regulatory filings, proprietary databases, and publicly available data to validate market dynamics and competitive positioning.

Data triangulation ensured the confirmation of quantitative trends with qualitative perspectives, while rigorous quality control processes guaranteed the accuracy and reliability of all findings. Segmentation methodologies adhered to standardized definitions of product class, mechanism of action, route of administration, distribution channel, and end user, providing a consistent basis for cross-comparisons and regional analyses. This meticulous approach underpins the actionable recommendations and strategic insights tailored for stakeholders at every level of the ankylosing spondylitis value chain.

Converging Insights Highlight the Path Forward for Ankylosing Spondylitis Management

The evolving ankylosing spondylitis market presents a convergence of scientific breakthroughs, reimbursement innovations, and regional disparities that require a cohesive strategic approach. The rise of IL-17 and IL-12/23 biologics alongside next-generation small molecules is redefining treatment standards, while tariff adjustments and payer negotiations are reshaping access economics. Segmentation analyses highlight the critical importance of selecting product formats and distribution pathways that align with patient preferences and clinical workflows.

Regional insights point to varied adoption curves, with mature markets leading on innovation and emerging economies prioritizing cost containment. Leading companies are capitalizing on strategic partnerships, pipeline diversification, and digital health integrations to secure market leadership. As stakeholders navigate this complex terrain, they must remain agile, data-driven, and collaborative to deliver on unmet patient needs and drive sustainable growth. The collective insights offered here serve as a strategic blueprint for optimizing decision-making and shaping the future of ankylosing spondylitis management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Class
    • Biologics
      • Il-12/23 Inhibitors
      • Il-17 Inhibitors
      • Tumor Necrosis Factor Inhibitors
    • Small Molecules
      • Conventional Dmards
      • Corticosteroids
      • Jak Inhibitors
      • Nonsteroidal Anti-Inflammatory Drugs
  • Mechanism Of Action
    • Corticosteroids
    • Cox Inhibitors
    • Il-17 Inhibitors
    • Jak Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Injectable
      • Intravenous Infusion
      • Subcutaneous Injection
    • Oral
      • Solutions
      • Tablets
    • Topical
      • Creams
      • Gels
  • Distribution Channel
    • Homecare
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • End User
    • Homecare Centers
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Sandoz International GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ankylosing Spondylitis Market, by Product Class
8.1. Introduction
8.2. Biologics
8.2.1. Il-12/23 Inhibitors
8.2.2. Il-17 Inhibitors
8.2.3. Tumor Necrosis Factor Inhibitors
8.3. Small Molecules
8.3.1. Conventional Dmards
8.3.2. Corticosteroids
8.3.3. Jak Inhibitors
8.3.4. Nonsteroidal Anti-Inflammatory Drugs
9. Ankylosing Spondylitis Market, by Mechanism Of Action
9.1. Introduction
9.2. Corticosteroids
9.3. Cox Inhibitors
9.4. Il-17 Inhibitors
9.5. Jak Inhibitors
9.6. Tumor Necrosis Factor Inhibitors
10. Ankylosing Spondylitis Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous Infusion
10.2.2. Subcutaneous Injection
10.3. Oral
10.3.1. Solutions
10.3.2. Tablets
10.4. Topical
10.4.1. Creams
10.4.2. Gels
11. Ankylosing Spondylitis Market, by Distribution Channel
11.1. Introduction
11.2. Homecare
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
11.6. Specialty Pharmacy
12. Ankylosing Spondylitis Market, by End User
12.1. Introduction
12.2. Homecare Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Ankylosing Spondylitis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Ankylosing Spondylitis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Ankylosing Spondylitis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. Amgen Inc.
16.3.5. Eli Lilly and Company
16.3.6. Galapagos NV
16.3.7. Gilead Sciences, Inc.
16.3.8. Sandoz International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANKYLOSING SPONDYLITIS MARKET MULTI-CURRENCY
FIGURE 2. ANKYLOSING SPONDYLITIS MARKET MULTI-LANGUAGE
FIGURE 3. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 161. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 162. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 213. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 218. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 231. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 232. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 233. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 236. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 237. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 238. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 248. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 273. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 276. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 278. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 283. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 286. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 287. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 288. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 301. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 303. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 308. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 311. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 312. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 316. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 317. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 318. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MA

Companies Mentioned

The companies profiled in this Ankylosing Spondylitis market report include:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Sandoz International GmbH

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.09 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.07 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Ankylosing Spondylitis Market Report 2025 - Product Image

Ankylosing Spondylitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Ankylosing Spondylitis - Global Strategic Business Report - Product Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From

About the Ankylosing Spondylitis Drug Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.